CILostazol-based triple anti-platelet therapy ON Ischemic Complication after drug-eluting stenT implantation - CILON-T

Description:

Multiple recent studies have demonstrated that hypo- or non-responsiveness to clopidogrel is associated with adverse clinical outcomes after percutaneous coronary intervention (PCI). Cilostazol is a phosphodiesterase IIIA enzyme antagonist that has been shown to reduce clinical events in small studies of patients undergoing PCI. The current trial sought to investigate whether triple antiplatelet therapy (TAT) with cilostazol, aspirin, and clopidogrel is superior to dual antiplatelet therapy (DAT...